Atea Pharmaceuticals Analyst Ratings
Atea Pharmaceuticals Analyst Ratings
While ratings are subjective and will change, the latest Atea Pharmaceuticals (AVIR) rating was a downgraded with a price target of $0.00 to $0.00. The current price Atea Pharmaceuticals (AVIR) is trading at is $3.54, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2023 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 03/16/2023 | 125.99% | JP Morgan | $12 → $8 | Maintains | Neutral |
| 01/27/2023 | 69.49% | SVB Leerink | $8 → $6 | Maintains | Market Perform |
| 01/24/2023 | 12.99% | Morgan Stanley | $7 → $4 | Maintains | Underweight |
| 08/15/2022 | 97.74% | Morgan Stanley | $6 → $7 | Maintains | Underweight |
| 03/02/2022 | 125.99% | JP Morgan | $10 → $8 | Maintains | Neutral |
| 03/01/2022 | 154.24% | SVB Leerink | $10 → $9 | Maintains | Market Perform |
| 02/16/2022 | 182.49% | SVB Leerink | $11 → $10 | Maintains | Market Perform |
| 01/06/2022 | 97.74% | Morgan Stanley | $14 → $7 | Downgrades | Equal-Weight → Underweight |
| 11/18/2021 | 210.73% | SVB Leerink | → $11 | Downgrades | Outperform → Market Perform |
| 10/20/2021 | 464.97% | SVB Leerink | $60 → $20 | Maintains | Outperform |
| 10/20/2021 | 351.98% | JP Morgan | $61 → $16 | Downgrades | Overweight → Neutral |
| 10/05/2021 | 1453.67% | Morgan Stanley | → $55 | Downgrades | Overweight → Equal-Weight |
| 09/09/2021 | 1594.92% | SVB Leerink | → $60 | Initiates Coverage On | → Outperform |
| 08/18/2021 | 945.2% | Morgan Stanley | $35 → $37 | Maintains | Overweight |
| 06/03/2021 | 888.7% | Morgan Stanley | $82 → $35 | Maintains | Overweight |
| 04/06/2021 | 2216.38% | Morgan Stanley | $49 → $82 | Maintains | Overweight |
| 01/29/2021 | 1764.41% | JP Morgan | $45 → $66 | Maintains | Overweight |
| 11/25/2020 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 11/24/2020 | 1171.19% | JP Morgan | → $45 | Initiates Coverage On | → Overweight |
| 11/24/2020 | — | William Blair | Initiates Coverage On | → Outperform | |
| 11/24/2020 | 1284.18% | Morgan Stanley | → $49 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/10/2023 | — | 摩根大通 | 降级 | 中性 → 体重不足 | |
| 03/16/2023 | 125.99% | 摩根大通 | 12 美元 → 8 美元 | 维护 | 中立 |
| 01/27/2023 | 69.49% | SVB Leerink | 8 美元 → 6 美元 | 维护 | 市场表现 |
| 01/24/2023 | 12.99% | 摩根士丹利 | 7 美元 → 4 美元 | 维护 | 体重不足 |
| 08/15/2022 | 97.74% | 摩根士丹利 | 6 美元 → 7 美元 | 维护 | 体重不足 |
| 03/02/2022 | 125.99% | 摩根大通 | 10 美元 → 8 美元 | 维护 | 中立 |
| 03/01/2022 | 154.24% | SVB Leerink | 10 美元 → 9 美元 | 维护 | 市场表现 |
| 2022 年 2 月 16 日 | 182.49% | SVB Leerink | 11 美元 → 10 美元 | 维护 | 市场表现 |
| 01/06/2022 | 97.74% | 摩根士丹利 | 14 美元 → 7 美元 | 降级 | 等重 → 减重 |
| 11/18/2021 | 210.73% | SVB Leerink | → 11 美元 | 降级 | 跑赢大盘 → 市场表现 |
| 2021 年 10 月 20 日 | 464.97% | SVB Leerink | 60 美元 → 20 美元 | 维护 | 跑赢大盘 |
| 2021 年 10 月 20 日 | 351.98% | 摩根大通 | 61 美元 → 16 美元 | 降级 | 超重 → 中性 |
| 2021 年 5 月 10 日 | 1453.67% | 摩根士丹利 | → 55 美元 | 降级 | 超重 → 重量相等 |
| 2021 年 9 月 9 日 | 1594.92% | SVB Leerink | → 60 美元 | 启动覆盖开启 | → 跑赢大盘 |
| 2021 年 8 月 18 日 | 945.2% | 摩根士丹利 | 35 美元 → 37 美元 | 维护 | 超重 |
| 06/03/2021 | 888.7% | 摩根士丹利 | 82 美元 → 35 美元 | 维护 | 超重 |
| 04/06/2021 | 2216.38% | 摩根士丹利 | 49 美元 → 82 美元 | 维护 | 超重 |
| 2021 年 1 月 29 日 | 1764.41% | 摩根大通 | 45 美元 → 66 美元 | 维护 | 超重 |
| 11/25/2020 | — | Evercore ISI 集团 | 启动覆盖开启 | → 跑赢大盘 | |
| 11/24/2020 | 1171.19% | 摩根大通 | → 45 美元 | 启动覆盖开启 | → 超重 |
| 11/24/2020 | — | 威廉布莱尔 | 启动覆盖开启 | → 跑赢大盘 | |
| 11/24/2020 | 1284.18% | 摩根士丹利 | → 49 美元 | 启动覆盖开启 | → 超重 |
What is the target price for Atea Pharmaceuticals (AVIR)?
Atea Pharmicals（AVIR）的目标价格是多少？
The latest price target for Atea Pharmaceuticals (NASDAQ: AVIR) was reported by JP Morgan on August 10, 2023. The analyst firm set a price target for $0.00 expecting AVIR to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.
摩根大通于2023年8月10日公布了Atea Pharmicals（纳斯达克股票代码：AVIR）的最新目标股价。这家分析公司将目标股价定为0.00美元，预计AVIR将在12个月内跌至-100.00％（可能下跌-100.00％）。去年有5家分析公司公布了评级。
What is the most recent analyst rating for Atea Pharmaceuticals (AVIR)?
Atea Pharmicals（AVIR）的最新分析师评级是多少？
The latest analyst rating for Atea Pharmaceuticals (NASDAQ: AVIR) was provided by JP Morgan, and Atea Pharmaceuticals downgraded their underweight rating.
Atea Pharmicals（纳斯达克股票代码：AVIR）的最新分析师评级由摩根大通提供，Atea Pharmicals下调了其减持评级。
When is the next analyst rating going to be posted or updated for Atea Pharmaceuticals (AVIR)?
Atea Pharmicals（AVIR）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atea Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atea Pharmaceuticals was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与Atea Pharmicals的高管和客户交谈以及听取财报电话会议）后得出股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Atea Pharmicals的最新评级是在2023年8月10日提交的，因此您应该预计下一个评级将在2024年8月10日左右公布。
Is the Analyst Rating Atea Pharmaceuticals (AVIR) correct?
分析师对Atea Pharmicals（AVIR）的评级是否正确？
While ratings are subjective and will change, the latest Atea Pharmaceuticals (AVIR) rating was a downgraded with a price target of $0.00 to $0.00. The current price Atea Pharmaceuticals (AVIR) is trading at is $3.54, which is out of the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的Atea Pharmicals（AVIR）评级被下调，目标股价为0.00美元至0.00美元。Atea Pharmicals（AVIR）目前的交易价格为3.54美元，超出了分析师的预测区间。